Eli Lilly Studies Experimental Covid-19 Drug in Nursing Homes
Late-stage trial explores whether antibody drug can help reduce infections in facilities with a diagnosed coronavirus case
Eli Lilly said that if testing is successful, its drug could get government approval by the end of the year.
Eli Lilly LLY +1.66% & Co. has started a study exploring whether its experimental Covid-19 drug can prevent infections among vulnerable residents and staff at nursing homes and other long-term care facilities.
Indianapolis-based Lilly said Monday that it is testing its antibody-based drug in senior homes that have had a recently diagnosed case of Covid-19, putting residents and staff at high risk of exposure.
The study, which aims to enroll up to 2,400 subjects, will track whether Lilly’s drug reduces the rate of infection and disease in the weeks after dosing.
Lilly has been exploring whether the drug, code-named LY-CoV555, could treat other kinds of Covid-19 patients. Studies already under way are testing whether the drug is safe for hospitalized Covid-19 patients, and whether it can clear viral loads and keep patients with milder disease out of the hospital.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE
Categories: The Muslim Times